The burden of the HIV infection is mainly concentrated in resource-limited countries.
There, anti-HIV therapy is based on efavirenz- or nevirapine-combination therapies.
The variability of drugs' pharmacokinetics is driven by different genetic backgrounds.
Another cause of pharmacokinetic's variation is drug–drug interaction.
We explore pharmacogenetic interactions among HIV, TB and antimalarial drugs.